Topics

FDA approves BMS' Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry

08:15 EDT 26 Mar 2020 | Pharmafile

Bristol-Myers Squibb has secured approval with the FDA for Zeposia (ozanimod) 0.92mg in relapsing forms of multiple sclerosis (RMS), but confirmed the drug wouldn’t be racing to market, as is usually the case.

read more

Original Article: FDA approves BMS' Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry

NEXT ARTICLE

More From BioPortfolio on "FDA approves BMS' Zeposia in relapsing multiple sclerosis, but COVID-19 will delay its market entry"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...